Ann: Investor Presentation, page-37

Those things would only hold value to a buyer who is interested in utilising them. I guess we'll see what the market is like for that with the sale of TAS.

The one thing I can't wrap my head around is the continued funding of indoor growing facilities. I guess it might make sense if you control the entire chain right through to sale of the product to the patient here in Aus, but they are going to have to hope that the current SAS remains in place so they can retain control of it. If it ever gets to the point where patients can hand in a prescription at their local pharmacy the low cost options (similar to generics) are going to dominate. This would be the biggest tailwind for ECS.